Last reviewed · How we verify
IN-C006 inj.
IN-C006 inj. is a PD-1 inhibitor Small molecule drug developed by HK inno.N Corporation. It is currently in Phase 3 development for Non-small cell lung cancer, PD-L1 positive. Also known as: IN-C006 inj.
IN-C006 inj. is a monoclonal antibody targeting PD-1.
IN-C006 inj. is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IN-C006 inj. |
|---|---|
| Also known as | IN-C006 inj |
| Sponsor | HK inno.N Corporation |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301 (PHASE3)
- Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IN-C006 inj. CI brief — competitive landscape report
- IN-C006 inj. updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI
Frequently asked questions about IN-C006 inj.
What is IN-C006 inj.?
How does IN-C006 inj. work?
What is IN-C006 inj. used for?
Who makes IN-C006 inj.?
Is IN-C006 inj. also known as anything else?
What drug class is IN-C006 inj. in?
What development phase is IN-C006 inj. in?
What are the side effects of IN-C006 inj.?
What does IN-C006 inj. target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: HK inno.N Corporation — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer, PD-L1 positive
- Also known as: IN-C006 inj
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing